Lymph node microenvironment provides chronic lymphocytic leukaemia (CLL) cells with signals promoting their survival and granting resistance to chemotherapeutics.
pathway, NFjB pathway and increased expression of E2F target genes. 5 Trafficking of neoplastic B cells to these proliferation-conducive compartments is controlled by chemokines. 6, 7 One of the key chemokines involved in CLL cells homing is CXCL12 (formerly stromal-cell derived factor 1, SDF1). Activation of CXCR4 induces CLL cells chemotaxis, transendothelial migration and exhibits direct antiapoptotic effects. [8] [9] [10] [11] Given the role of CXCR4 in CLL cell motility and viability, mechanisms regulating CXCR4 activity and CXCR4-triggered signal transduction are particularly interesting as potential therapeutic targets. Accordingly, highly active B-cell receptor signalling inhibitors, such as ibrutinib, lead to egress of CLL cells from the lymphoid compartments to a periphery in a mechanism that involves decrease of surface CXCR4 expression. kinases, which phosphorylate CXCR4 on serine 339. 9 PIMs have been postulated as a key mechanism downstream of BCR, responsible for modulation of CXCR4 in CLL. 8, 10 The family of PIM proteins involves three conserved oncogenic serine/threonine kinases, PIM1, PIM2 and PIM3. PIMs phosphorylate a broad range of substrates, which are engaged in cell growth, metabolism, proliferation, migration and drug resistance. [12] [13] [14] transcript abundance, using the 2 ÀDDCT method. 19 Primer sequences are given in Table S1 .
| Chemicals, apoptosis and migration assays
Pan-PIM kinase inhibitors SEL24-B489 and AZD1208 were kindly provided by Selvita S.A. 20 The mTOR inhibitor OSI-027 was pur- cells migrated into the lower chamber were counted using trypan blue exclusion assay.
| Immunoblotting
Protein extracts were prepared using RIPA buffer as previously described. 21 Protein extracts were PAGE-separated, electrotransferred to PVDF membranes (Millipore) and immunoblotted with primary and appropriate secondary antibodies ( 
| CXCR4 surface expression
Chronic lymphocytic leukaemia cells were incubated for 2-10 hours with 10 lmol/L SEL24-B489 or vehicle (DMSO), washed and stained with APC-conjugated CXCR4 antibody or APC-conjugated mouse IgG2a, j as an isotype control (Table S2) , and analysed using the FACS Canto II.
| Statistical analysis
Comparisons between variables were performed with GraphPad Prism 6 software (GraphPad, La Jolla, CA, USA), using indicated tests; P < .05 was considered statistically significant.
| RESULTS

| PIM1 and PIM2 are associated with unfavourable CLL prognosis
Given the established oncogenic function of PIM kinases in CLL cells, 9, 22 we first assessed the expression of PIM1, PIM2 and PIM3
on both transcript and protein levels in a group of 88 newly diag- 
| Microenvironment signals induce PIM expression
Chronic lymphocytic leukaemia cell fate depends on microenvironment signals, which promote anti-apoptotic and proliferative circuitry involving STAT and NFjB transcription factors. 6, 7 Since these transcription factors are known PIM inducers, 23 we hypothesized that 
| PIM inhibitor SEL24-B489 induces apoptosis in CLL cells
We next investigated the consequences of PIM inhibition in CLL cells using newly developed pan-PIM inhibitor, SEL24-B489. 20, 25, 26 Incubation of CLL cells with 1-10 lmol/L SEL24-B489 for 24 hours caused a significant, dose-dependent decrease in phosphorylation of PIM substrates: threonine 24/threonine 32 (T24/T32) of FOXO1/3a, serine 65 (S65) of 4EBP1 and serine 112 (S112) of BAD ( Figure 3A -C). SEL24-B489 inhibitor decreased phosphorylation of these substrates irrespective of IGHV gene mutation status ( Figure 3A , right panel). Similar effects were also observed with a referential pan-PIM inhibitor, AZD1208, indicating that SEL24-B489 induces expected, specific biochemical effects ( Figure 3A, left panel) . 27 In contrast, SEL24-B489 did not decrease the phosphorylation of FOXO1/3 and 4EBP1 in normal B lymphocytes ( Figure S4A ). Having confirmed inhibitor's on-target activity, we next assessed the effect of SEL24-B489
(1-10 lmol/L, 48 hours) on viability of CD19+ CLL cells obtained from peripheral blood of 23 treatment-na€ ıve patients and 5 healthy individuals (Table S3) . Incubation with SEL24-B489 for 48 hours did not perturb normal B-cells viability; in marked contrast, SEL24-B489 triggered a dose-dependent increase in apoptosis of CLL cells (Figure 3D , Figure S4B ). Cells obtained from IGHV-unmutated and IGHV-mutated CLL patients were equally susceptible to SEL24-B489-induced apoptosis ( Figure 3D , Table S3 ). CLL cells obtained from 5 patients who progressed after initial treatment also responded to the inhibitor, reaching 39%-83% of apoptotic cells for a 10 lmol/L SEL24-B489 dose ( Figure 3D , Table S3 ). Importantly, CLL cells carrying del17p13/TP53 point mutations were similarly sensitive to SEL24-B489 as p53-wild-type cells ( Figure 3D 
| SEL24-B489 impairs CXCR4-dependent migration
PIM1 phosphorylates CXCR4 on serine 339 (S339) and increases CXCR4 surface expression and recycling. 8, 9, 25 We thus explored whether pan-PIM inhibitor SEL24-B489 affects p-CXCR4 levels and CXCR4-driven migration in CLL cells. SEL24-B489 caused timedependent reduction in p-CXCR4 (S339) levels within 8 hours in all analysed samples ( Figure 4A ). These changes were followed by a decrease in CXCR4 surface expression, with the most noticeable BIALOPIOTROWICZ ET AL.
| 3551 F I G U R E 1 PIM expression is associated with CLL clinical parameters. PIM1/2 transcript levels were assessed by qPCR in 88 newly diagnosed CLL patients. Relative abundance of PIM1/2 transcripts was determined using 2 ÀDDCT method, with GAPDH used as a reference gene. PIM1/2 protein expression was determined by densitometric quantification of Western blots. GAPDH protein was used as a loading control. (A) PIM1 protein and PIM2 transcript/protein levels are significantly higher in patients with advanced CLL (Binet C), compared to subjects in earlier disease stages (Binet A/B). Please see Supplemental Figure 2A for example source Western blots. (B) PIM1 protein and PIM2 transcript/protein levels (at diagnosis) are higher in patients who eventually progressed after first-line treatment. Please see Supplemental Figure 2B for example source Western blots. (C) PIM1 transcript abundance is significantly elevated in patients with unmutated IGHV status (U-CLL) comparing to subjects with mutated IGHV configuration (M-CLL). Statistics were calculated using one-way ANOVA followed by Tukey's post-hoc test for three-group comparison and Mann-Whitney test for comparison between two groups. *** for P < .001, ** for P < .01 and * for P < .05; "n" refers to the number of patients. GAPDH was used as a housekeeping reference for qPCR analyses. 
| PIMs modulate mTOR activity downstream of CXCR4
Given the marked decrease in CXCR4-driven migration caused by PIM inhibition and its relatively moderate effect on CXCR4 surface expression, we hypothesized that PIM kinases influence CXCR4-driven migration by an additional mechanism. We found that incubation of leukaemia cells with CXCL12 led to increased phosphorylation of mTOR (S2448) and AKT (S473), revealing CXCL12-mediated activation of this pathway in CLL ( Figure 5A ). To determine whether PIM inhibition interferes with mTOR pathway, we first incubated CLL cells with SEL24-B489 and found decreased phosphorylation of mTOR pathway components, including p-mTOR (S2448), p-TSC2 (S1798) and p-AKT (S473; Figure 5B ). Consistent with this, we also found decreased phosphorylation of direct mTOR substrates, 4EBP1 serine 37 and threonine 46 (S37/T46), indicating that PIM inhibition blocks signalling through mTOR pathway (Fig- ure 5B). 29 We next determined whether PIM inhibition could block CXCL12-mediated mTOR activation. As expected, SEL24-B489 or OSI-027 (an mTORC1/2 inhibitor) markedly decreased CXCL12-induced phosphorylation of mTOR pathway components, demonstrating that PIM inhibitors block CXCR4-dependent mTOR activation and signalling ( Figure 5C ). We next investigated the impact of mTOR inhibition on CXCR4-dependent migration. For these F I G U R E 2 Microenvironment signals induce the expression of PIM kinases. CLL cells from 7 donors were incubated with 10 lg/mL antiIgM (a-IgM) for 8 h and 24 h (A) or CD40L (50 ng/mL, 1 h) (B), or co-cultured with HS5 cells for 48 h (C), and then collected for qPCR analyses. PIM1/2/3 transcript abundance was quantified using 2 ÀDDCT method, where GAPDH was used as a reference gene. The results are expressed relative to the value of untreated sample, assigned to an arbitrary value 1. * for P < .05; Wilcoxon matched pairs test.
BIALOPIOTROWICZ ET AL. Primary CLL cells were pretreated with SEL24-B489 or OSI-027 (both at 10 lmol/L) and placed in a transwell chamber in CXCL12 gradient. Numbers of migrated cells were determined after 6 h using trypan blue exclusion assay. Bars represent mean AE SD from triplicates, ***P < .001, **P < .01 and *P < .05 calculated with Mann-Whitney test.
signalling or ligation of TNF family receptors, such as CD40. 34, 35 Of note, both these receptors lead also to a delayed induction of STATs activity, cooperating with NFjB in PIMs transcriptional regulation. 36, 37 gatekeeper site, restoring its pro-apoptotic activity. 40 In addition, inhibition of PIM-dependent protein translation decreases abundance of an antiapoptotic BCL2 family protein, MCL1. 30 We show here that PIM kinase inhibition also markedly reduced the expression of MCL1 protein induced by stromal cell contact. Thus, PIM inhibition triggers proapoptotic mechanisms that are not blocked, or only partially blocked, by microenvironmental support, resulting in p53-independent cell death. 41 The homing of CLL cells to a proliferation-conducive and protective lymphoid compartments is predominantly regulated by CXCR4 chemokine receptor. 6 Thus, interference with the activation of CXCR4 receptor in CLL cells facilitates their egress from the lymph node niche and/or prevents their homing to lymphoid organs. overlapping, yet highly complementary functions, whereby PIM1 is essential for CXCR4-dependent CLL cell migration and PIM2/3 for cell survival. 9, 15, 46 Thus, inhibition of all PIM isoforms is a rational approach, excluding possibility of isoform redundancy or compensation issues. In this study, we utilized a newly developed, small molecule pan-PIM inhibitor, SEL24-B489, which previously showed favourable toxicity profile and encouraging results in preclinical AML models. 25 SEL24-B489 is currently under clinical development in a phase I/II trial in AML patients (clinicaltrials.gov: NCT03008187).
Taken together, our results suggest that SEL24-B489 pan-PIM
